



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

AF *[signature]*

Application of: Arjan Scheepens
Serial No.: 09/786,982
Filed: February 27, 2002
For: Neuroprotective Effect of Growth Hormone

Examiner: Stephen Gucker
Group Art Unit: 1649
Confirmation No.: 8750

Attorney Docket No.: NRNZ-01006US0

Mail Stop Amendment
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

This Information Disclosure Statement is being filed in connection with the patent application referenced above. The Examiner is requested to consider each of the references cited herein and forward an initialed copy of the enclosed PTO Form 1449 to the undersigned representative. This Statement is being filed:

- ☐ Upon filing the application.
- ☐ Within three months from the filing date of this application, which is not a continued prosecution application.
- ☐ Within three months from date of entry of the national stage for this application.
- ☐ Before the mailing date of a first Office action on the merits for this application.
- ☐ Before the mailing date of a first Office action after the filing of a request for continued examination.

☒ Before the mailing date of any of: (i) a Final Office Action, (ii) a Notice of Allowance, and (iii) any other action that closes prosecution of this application. The Statement is accompanied by:

- ☐ A Statement pursuant to 37 C.F.R. §1.97(e) or
- ☒ The fee set forth in 37 C.F.R. §1.17(p), believed to be \$180.00.
- ☐ Before payment of the Issue Fee. The Statement is accompanied by:
- ☐ A Statement pursuant to 37 C.F.R. §1.97(e) and
- ☐ The fee set forth in 37 C.F.R. §1.17(p), believed to be _____.

I. Provision of Copies

☒ A copy of each of the references listed on the attached Form PTO Form 1449 is enclosed herewith and forms a part hereof.

☐ A translation of References AA, AB and AC are enclosed herewith and form a part hereof.

☐ A copy of the European Search Report from a corresponding or related EPO application is enclosed herewith.

☐ A copy of the International Search Report from a corresponding or related PCT application is enclosed herewith.

☐ This application claims priority, pursuant to 35 U.S.C. §120, to prior U.S. Application No. _____, filed _____. References not submitted herewith were submitted to or cited by the Office in the prior application(s).

II. Fee

☐ No fee is believed due in connection with filing of this Statement. However, in the event a fee or refund is due, the Commissioner is authorized to charge any fee associated with this communication or credit any overpayment to Deposit Account No. 50-4089.

☐ The fee in the amount \$_____ that is due in connection of filing of this Statement was paid upon electronic filing of a corresponding Statement, which was made on _____ using the ePAVE software.


☒ The fee set forth in 37 C.F.R. §1.17(p), believed to be \$180.00, is believed to be due in connection of filing of this Statement.

☒ A check in the amount \$180.00 is enclosed.


☒ The Commissioner is authorized to charge any other fee associated with this communication, or credit any overpayment, to Deposit Account No. 50-4089.

Respectfully submitted,

Dated: March 26, 2007


D. Benjamin Borson, Ph.D.
Reg. No. 42,349

BORSON LAW GROUP, PC
1320 Willow Pass Rd., Suite 490
Concord, California 94520
Tel: (925) 395-2060
Fax: (925) 395-2061



Approved for use through 03/31/2007. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Buyers for form 1449/PTO

(Use as many sheets as necessary)

Sheet	1	of	2
-------	---	----	---

Complete if Known

Application Number	09/786,982
Filing Date	2/27/2002
First Named Inventor	Arjan Scheepens
Art Unit	1649
Examiner Name	Stephen Gucker
Attorney Docket Number	NRNZ-01006US0

U. S. PATENT DOCUMENTS

[illegible]

FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear	T ⁶
		Country Code ² -Number ⁴ -Kind Code ⁵ (if known)	MM-DD-YYYY			
	1	WO 99/33481	07/08/1999	Applied Research Systems		
	2	EP 0720483	09/21/1993			

Examiner Signature		Date Considered	
-----------------------	--	--------------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. **DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.**

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Use as many sheets as necessary)		Complete if Known	
		Application Number	09/786,892
		Filing Date	2/27/2002
		First Named Inventor	Arjan Scheepens
		Art Unit	1649
		Examiner Name	Stephen Gucker
Sheet 2	of 2	Attorney Docket Number	NRNZ-01006US0

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	1	L. CHEN, et al., "Growth Hormone, Insulin-like Growth Factor I, and Motoneuron Size", Dept. of Physiology and Curriculum in Neurobiology, N.C., 25 Sept. 1996, pp. 202-212	
	2	CAROL J. PHELPS, "Stimulatory Effect of Human, but not Bovine, Growth Hormone Expression on Numbers of Tuberoinfundibular Dopaminergic Neurons in Transgenic Mice", Dept. of	
	2	Anatomy, Tulane Univ. School of Medicine, Endocrinology, Vol. 138, No. 7, pp. 2849-2855, 1997.	
	3	R. CLARK, et al., "Up and Down the Growth Hormone Cascade", Cytokine & Growth Factor Reviews, Vol. 7, No. 1, pp. 65-80, 1996.	
	4	S. A. LODDICK, et al., "Displacement of insulin-like growth factors from their binding proteins as a potential treatment for stroke", Proc. Nat'l. Acad. Sci. USA,	
	4	Pharmacology, Vol. 95, pp. 1894-1898, February 1998.	
	5	P. E. LOBIE, et al., "Localization and ontogeny of growth hormone receptor gene expression in the central nervous system", Developmental Brain Research, 74 (1993) 225-233.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.